Deliver Your News to the World

Healthcare: Earlier Detection and Treatment of Chronic Kidney Disease


Sep 28, 2009 – Saint Louis, MO, Lee Biosolutions, Inc has announced that it will increase its inventory and manufacturing capability of Human Cystatin C antigen which is fast becoming a renal protein marker of choice among researchers for early detection of acute renal failure because its unaffected by non-renal factors and demonstrates higher diagnostic accuracy and sensitivity .

According to publish reports there are over 26 million adults who fall into high risk groups having some form of Chronic kidney disease. High risk groups include those with high blood pressure, diabetes and family history among others. If Chronic kidney disease is not detected and treated early it may progress to kidney damage.

Current research supports Cystatin C as a more sensitive endogenous marker for estimation of Glomular Filtration Rate GFR. Cystatin C is a very small protein and is a member of the cysteine proteinase inhibitor family and is produced at a constant rate by all nucleated cells. Since Cystatin C is only 13kDa which is considered a small protein , Cystatin C is fully reabsorbed and broken down by the renal tubules and not secreted . When the kidneys are functioning normally, concentrations of Cystatin C in the blood are stable, but as kidney function deteriorates, the concentrations begin to rise . Research also supports that Cystatin C levels are unaffected by race, age , mass or gender making it the most sensitive of markers during early stages of Chronic Kidney Disease.

"Studies are showing that earlier detection of renal disease by utilizing CYSTATIN C as a renal marker my help prevent the progression of kidney disease to kidney failure . If you can prevent future high risk groups to avoid kidney dialysis you not only improve quality of life but will ultimately save millions of dollars in healthcare cost. ” Burton Lee , President of Lee Biosolutions said.

According to Burton Lee , “Lee Biosolutions is in constant communication with its customers to determine trends and anticipate product needs before they happen. Innovative purification procedures continues to be key to the success of Lee Biosolutions business. We are offering cystatin C antigen and cystatin C positive urine from patients for research ”

“We understand the critical role our products play in the clinical research process”, Lee said. By maintaining higher purity and quality standards, we aim to provide clients with a wider variety of reliably consistent products which makes us the preferred producer of kidney proteins.

Lee Biosolutions Inc is a leader in the development and marketing of high valued specialty products such as Cystatin C and Renin but also, recombinant proteins, coenzymes, antigens and antibodies for both research and industrial applications.

Working closely with major diagnostic companies and clinical researchers worldwide in autoimmune studies, cardiovascular and cancer research, Lee Biosolutions, Inc delivers over 400 products to more than 40 countries around the globe. To learn more about how LEE BIOSOLUTIONS helps to make research work, visit


 cystatin C
 kidney disease
 chronic kidney disease

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.